Tonix Pharma (TPM0) Price & Analysis

9 Followers

TPM0 Stock Chart & Stats

€12.70

Market closed

€12.70

Day’s Range― - ―

52-Week Range€8.85 - €58.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)0.00

Market Cap

€174.20M

Enterprise Value€10.30M

Total Cash (Recent Filing)€185.47M

Total Debt (Recent Filing)€1.29M

Price to Earnings (P/E)―

Beta0.09

Next Earnings

Aug 10, 2026

EPS Estimate

-2.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.66

Shares OutstandingN/A

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.54

Price to Sales (P/S)10.14

P/FCF Ratio-1.29

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€33.03

Price Target Upside160.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-9.1

Revenue Forecast (FY)€27.22M

Bulls Say, Bears Say

Bulls Say

Low LeverageExtremely low debt reduces solvency and refinancing risk for a clinical-stage biotech. With minimal interest burden, management can prioritize R&D and commercialization investments without near-term debt constraints, giving structural financial flexibility versus leveraged peers.

Improving Revenue & MarginsSustained revenue growth and meaningful gross margin expansion suggest improving commercial traction or higher-margin product mix. If maintained, better gross margins help lower the cash needed per revenue dollar and structurally improve the pathway to positive operating leverage as scale builds.

Pipeline AdvancementAdvancing a program into a potentially pivotal Phase 2 is a durable operational milestone that can materially de-risk the asset, enable regulatory discussions, and create licensing or commercialization optionality. Successful progression strengthens long-term revenue prospects.

Bears Say

Heavy Cash BurnSustained large negative operating and free cash flows indicate the business consumes material cash to fund R&D and operations. This creates ongoing funding needs, elevates dilution or financing risk, and limits runway until either revenues scale or costs are materially reduced.

Large Net Losses & Weak ROEDeeply negative profitability metrics and severely negative ROE indicate current operations destroy shareholder capital. Over the medium term, this underscores a long path to sustainable profits and the risk that growth investments do not translate into positive returns.

No Material Recurring RevenueReliance on future regulatory approvals, commercialization, or licensing means revenue is uncertain and binary. Without established recurring sales, the firm remains exposed to trial outcomes, payer acceptance, and partner negotiations, creating structural revenue execution risk.

Tonix Pharma News

Tonix Pharmaceuticals enrolls first patient in HORIZON study

Tonix Pharmaceuticals (TNXP) announced that the first patient has been enrolled in HORIZON, a potentially pivotal Phase 2...

3d ago

TNXP

Qualcomm upgrade, Intel initiation among today’s top calls on Wall Street

The most talked about and market moving research calls around Wall Street are now in one place. Here...

7d ago

KDP

Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Tonix Pharmaceuticals (TNXP) with a Strong Buy rating and $26 price target TNX-4800...

8d ago

TNXP

Tonix Pharmaceuticals secures second commercial agreement for Tonmya

Tonix Pharmaceuticals (TNXP) announced an agreement with a second group purchasing organization, or GPO, that provides coverage for...

24d ago

TNXP

Tonix Pharma Begins Pivotal Phase 2 Depression Trial

Tonix Pharma ( ($TNXP) ) has provided an announcement. On June 29, 2026, Tonix Pharmaceuticals Holding Corp. reported...

3d ago

TNXP

Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($TTWO) ), ( ($QNCX) ), ( ($TNXP) ), ( ($CRWV)...

5d ago

AFRM

CRWV

Fiserv, ZIM, Carvana, Tonix, Ulta: Insider Moves Exposed

Insiders have been trading these 5 stocks: (($FISV)), (($ZIM)), (($CVNA)), (($TNXP)) and (($ULTA)). Here is a breakdown of...

12d ago

ZIM

CVNA

ZIM, Tonix, Axon, Illumina, Microchip Insider Shock

Insiders have been trading these 5 stocks: (($ZIM)), (($TNXP)), (($AXON)), (($ILMN)) and (($MCHP)). Here is a breakdown of...

19d ago

ZIM

AXON

Tonix Pharma Expands Coverage and Access for TONMYA

Tonix Pharma ( ($TNXP) ) has shared an announcement. On June 8, 2026, Tonix Pharmaceuticals announced it had...

24d ago

TNXP

Tonix Advances TNX-102 SL Into Phase 2 Depression Trial, Drawing Investor Focus

Tonix Pharmaceuticals ($TNXP) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2,...

30d ago

TNXP

Tonix presents data from analysis of opioid use in adults with fibromyalgia

Tonix Pharmaceuticals (TNXP) presented data from a real-world claims analysis of opioid use in U.S. adults with fibromyalgia...

1M ago

TNXP

Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology

Tonix Pharmaceuticals (TNXP) announced the publication of a paper, “First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500,...

1M ago

TNXP

Tonix Pharma Highlights Positive Phase 1 TNX-1500 Results

Tonix Pharma ( ($TNXP) ) has provided an update. On May 27, 2026, Tonix Pharmaceuticals announced the publication...

1M ago

TNXP

Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia

Tonix Pharmaceuticals (TNXP) presented data from a real-world claims analysis characterizing U.S. adults with fibromyalgia in a poster...

1M ago

TNXP

TPM0 FAQ

What was Tonix Pharmaceuticals’s price range in the past 12 months?

Tonix Pharmaceuticals lowest stock price was €8.85 and its highest was €58.00 in the past 12 months.

What is Tonix Pharmaceuticals’s market cap?

Tonix Pharmaceuticals’s market cap is €174.20M.

When is Tonix Pharmaceuticals’s upcoming earnings report date?

Tonix Pharmaceuticals’s upcoming earnings report date is Aug 10, 2026 which is in 39 days.

How were Tonix Pharmaceuticals’s earnings last quarter?

Tonix Pharmaceuticals released its earnings results on May 11, 2026. The company reported -€2.574 earnings per share for the quarter, missing the consensus estimate of -€2.258 by -€0.316.

Is Tonix Pharmaceuticals overvalued?

According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tonix Pharmaceuticals pay dividends?

Tonix Pharmaceuticals does not currently pay dividends.

What is Tonix Pharmaceuticals’s EPS estimate?

Tonix Pharmaceuticals’s EPS estimate is -2.32.

How many shares outstanding does Tonix Pharmaceuticals have?

Currently, no data Available

What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?

Tonix Pharmaceuticals reported an EPS of -€2.574 in its last earnings report, missing expectations of -€2.258. Following the earnings report the stock price went down -4.682%.

Which hedge fund is a major shareholder of Tonix Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:TPM0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tonix Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-67.65%

Trailing 12-Months

Asset Growth

33.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.

Tonix Pharma (TPM0) Earnings & Revenues

Historic Earnings Reports

TPM0 Stock 12 Month Forecast

Average Price Target

€33.03

▲(160.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"€9","21":"€21","33":"€33","45":"€45","57":"€57"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.99524545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.02801403,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€33.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.29069846,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,21,33,45,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.885,14.431941957692308,17.978883915384614,21.525825873076922,25.07276783076923,28.619709788461535,32.166651746153846,35.71359370384615,39.26053566153846,42.80747761923077,46.35441957692307,49.90136153461538,53.44830349230769,{"y":56.99524545,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.885,12.588308771538461,14.291617543076924,15.994926314615386,17.698235086153847,19.40154385769231,21.10485262923077,22.808161400769233,24.511470172307696,26.214778943846156,27.918087715384615,29.621396486923082,31.32470525846154,{"y":33.02801403,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.885,11.53159218923077,12.178184378461538,12.824776567692307,13.471368756923077,14.117960946153847,14.764553135384617,15.411145324615385,16.057737513846156,16.704329703076922,17.350921892307692,17.997514081538462,18.64410627076923,{"y":19.29069846,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.715,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.985,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.885,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >